The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s demonstrating significant potential in clinical trials for addressing obesity. Unlike some current weight loss treatments, retatrutide appears to offer a greater substantial re